Optimal dosing of rivaroxaban is undefined

Pages: i5549 - i5549
Published: Oct 18, 2016
Abstract
The faulty INRatio device used in the rivaroxaban ROCKET atrial fibrillation trial1 is particularly important in light of another drawback to this novel oral anticoagulant (NOAC). Rivaroxaban has the shortest terminal half life of the...
Paper Details
Title
Optimal dosing of rivaroxaban is undefined
Published Date
Oct 18, 2016
Journal
Pages
i5549 - i5549
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.